Difference between revisions of "Dosulepine-vortioxetine"

From Psychiatrienet
Jump to: navigation, search
Line 12: Line 12:
 
| info =  
 
| info =  
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
 +
{{review}}
 
}}
 
}}

Revision as of 14:19, 2 November 2015

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine

Switch medication from dosulepine to vortioxetine.

Nietinrijdenbord.png Stop dosulepine
  • Before day 1: gradually reduce dosage of dosulepine to a maximum of 75 mg/day.
  • Day 1: reduce dosage of dosulepine to 50 mg/day.
  • Day 3: reduce dosage of dosulepine to 25 mg/day.
  • Day 7: stop dosulepine
Eenrichtingbord.png Start vortioxetine
  • A wash-out period is not necessary.
  • Day 7: start administration of vortioxetine in a dosage of 10 mg/day.
Infobord.png More information
  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • This switch is currently being reviewed.
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2015; Monografie "dosulepine" (Dutch)
  2. NVZA; Toxicology.org; Monografie 63 (dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.